Abstract
Hemophilia B (HB), an X-linked bleeding disorder, is ideally suited for gene therapy. We investigated a novel approach using peripheral vein infusion of a single dose of a serotype-8 pseudotyped self-complementary adeno-associated virus (AAV) vector expressing a codon-optimized coagulation factor IX (FIX) transgene (scAAV2/8-LP1-hFIXco).
Six severe HB subjects (FIX ≤1%) were enrolled sequentially into one of three dose cohorts with two subjects in each group. Vector was administered without immunosuppression. The subjects were followed for 6–16 months post treatment.
AAV-mediated expression of FIX at 2–11% of normal was observed in all subjects. Four of the six have discontinued prophylaxis and remain free of spontaneous hemorrhage. The other two have increased the interval between FIX prophylaxes. A high-dose subject developed asymptomatic, transient elevation of serum transaminases associated with detection of AAV8 capsid specific T cells in peripheral blood. The second high-dose subject experienced a slight increase of liver enzymes, of less clear etiology. Treatment of each with a short course of steroids led to rapid normalization of the transaminases and maintenance of FIX levels in the 3–11% range.
Peripheral vein administration of scAAV2/8-LP1-hFIXco was well tolerated and resulted in FIX transgene expression at levels sufficient to improve the bleeding phenotype. Immune-mediated clearance of AAV-transduced hepatocytes remains a concern but our data suggest that this process may be controlled with a short course of steroids without loss of transgene expression. Hence, our novel approach shows promise for gene therapy of HB and other protein deficiencies. (ClinicalTrials.gov number, NCT00979238)
Nathwani:Amsterdam Molecular Therapeutics: Patents & Royalties. Gray:Amsterdam Molecular Therapeutics: Patents & Royalties. Davidoff:Amsterdam Molecular Therapeutics: Patents & Royalties.
![](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/21/10.1182_blood.v118.21.5.5/4/m_permbld2011abs03.jpeg?Expires=1724872545&Signature=zZAU8VOCeRWyuTp3GdnODIEa1ykXmfzMRKvLKPCIizwAEz0sIr8xA50z7fhm58n07B5Em6yTyy1MWyQZ91V6nrHAa3j0HD-Cy4GaAIKnW-wIr340UsC4s63Av42ZcKPuC4~UHqqDe~uibD2xvMohhzNew1L43KhyMjPLMRLfuNlR0N52QWo7-Ic-JvLr021lA8qHKMS5XG2mQHMXJaucOuGSQJvxyo1B50-xZ5pFFGGlyFODlJ~8MC6KjGKorPepIQiUo-V8mu8XYbegrKNLix4lKMmtLo7gUbr1~ktOtfR6lHmdVl04qfue0KkzP9NmPxa5UWOL~rdP4XsTqsQZlQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
This icon denotes a clinically relevant abstract
Author notes
Asterisk with author names denotes non-ASH members.